Trump's Pot Reclassification: A Regulatory Gift Wrapped in Optimism

The Trump administration is expected to reclassify marijuana as soon as Wednesday, according to an official familiar with the matter. This is the moment every cannabis-adjacent founder with a Substack has been waiting for: a regulatory tailwind to justify valuations that have no basis in actual revenue or competitive advantage. The move would ostensibly make it easier to study medicinal applications of marijuana. What it will actually do is make it easier to raise $50 million on a slide deck.

History suggests that regulatory clarity in emerging sectors produces exactly what you'd expect: a violent swarm of entrants with indistinguishable business models and identical pitch decks. The appeal is obvious—suddenly, the drug your uncle talked about at Thanksgiving is now a 'multi-billion dollar addressable market.' Influencer support is apparently now a material investment factor, which tells you everything you need to know about where the risk-adjusted returns are headed.

Within hours of any Wednesday announcement, expect press releases celebrating 'the democratization of cannabinoid research' and 'our commitment to unlocking natural wellness solutions.' What you won't hear: credible unit economics, customer acquisition costs, or evidence that medical efficacy requires venture capital at all.

Regulatory optimism has never been a substitute for a business. But it has always been an excellent substitute for due diligence.